← Leaderboards
David Marc Weinstock
Dana-Farber Cancer Inst
$10,844,261
Attributed
$10,844,261
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.8M · FY2010–23$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$14,446,541 · 9
By mechanism
P01$5,403,421 · 3
R01$5,176,320 · 2
R35$2,897,399 · 1
U54$732,197 · 1
P30$237,204 · 2
Top collaborators
No co-investigators on record.
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Andrew A Lane$4,246,865
- David S Pellman$18,057,380
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsIn VivoIn VitroInnovationMalignant NeoplasmsLaboratoriesBaseProgramsSignal TransductionClinical TrialsLeukemiaXenograft ProcedureMemberRecurrenceTranslatingDown SyndromeB-LymphocytesPhosphotransferasesMutationResearch PersonnelGenesPatient-Focused OutcomesResistanceCell Line
Grant awards (36)
Program 04 Leukemia$42,358
P30 · FY2023 · CA · contact PI
Program 04 Leukemia$42,358
P30 · FY2022 · CA · contact PI
Targeting High-Risk Lymphoid Neoplasms$1,021,025
R35 · FY2021 · CA · contact PI
Synergistic combinations that target apoptosis induction in PTCL$462,042
P01 · FY2021 · CA · contact PI
Biospecimens and Patient-derived xenografts$137,740
U54 · FY2021 · CA · contact PI
Administrative Core$131,838
P01 · FY2021 · CA · contact PI
Program 4: Leukemia$74,826
P30 · FY2021 · CA · contact PI
Informed Combination Strategies for Peripheral T-cell Lymphomas$1,735,168
P01 · FY2020 · CA · contact PI
Targeting High-Risk Lymphoid Neoplasms$1,077,706
R35 · FY2020 · CA · contact PI
Synergistic combinations that target apoptosis induction in PTCL$462,042
P01 · FY2020 · CA · contact PI
Biospecimens and Patient-derived xenografts$161,494
U54 · FY2020 · CA · contact PI
Administrative Core$131,838
P01 · FY2020 · CA · contact PI
Program 4: Leukemia$74,713
P30 · FY2020 · CA · contact PI
Program 4: Leukemia$2,949
P30 · FY2020 · CA · contact PI
Informed Combination Strategies for Peripheral T-cell Lymphomas$1,867,112
P01 · FY2019 · CA · contact PI
Targeting High-Risk Lymphoid Neoplasms$798,668
R35 · FY2019 · CA · contact PI
Synergistic combinations that target apoptosis induction in PTCL$481,543
P01 · FY2019 · CA · contact PI
CRLF2 signaling in B-cell acute lymphoblastic leukemia$381,181
R01 · FY2019 · CA · contact PI
Biospecimens and Patient-derived xenografts$140,893
U54 · FY2019 · CA · contact PI
Administrative Core$131,838
P01 · FY2019 · CA · contact PI
CRLF2 signaling in B-cell acute lymphoblastic leukemia$392,969
R01 · FY2018 · CA · contact PI
Biospecimens and Patient-derived xenografts$146,820
U54 · FY2018 · CA · contact PI
CRLF2 signaling in B-cell acute lymphoblastic leukemia$392,969
R01 · FY2017 · CA · contact PI
Polysomy 21 in Acute Lymphoblastic Leukemia$352,946
R01 · FY2017 · CA · contact PI
Biospecimens and Patient-derived xenografts$145,250
U54 · FY2017 · CA · contact PI
CRLF2 signaling in B-cell acute lymphoblastic leukemia$392,969
R01 · FY2016 · CA · contact PI
Polysomy 21 in Acute Lymphoblastic Leukemia$352,946
R01 · FY2016 · CA · contact PI
CRLF2 signaling in B-cell acute lymphoblastic leukemia$199,999
R01 · FY2016 · CA · contact PI
Polysomy 21 in Acute Lymphoblastic Leukemia$352,946
R01 · FY2015 · CA · contact PI
Polysomy 21 in Acute Lymphoblastic Leukemia$342,358
R01 · FY2014 · CA · contact PI
CRLF2 signaling in B-cell acute lymphoblastic leukemia$324,410
R01 · FY2014 · CA · contact PI
Polysomy 21 in Acute Lymphoblastic Leukemia$352,946
R01 · FY2013 · CA · contact PI
CRLF2 signaling in B-cell acute lymphoblastic leukemia$314,376
R01 · FY2013 · CA · contact PI
CRLF2 signaling in B-cell acute lymphoblastic leukemia$334,437
R01 · FY2012 · CA · contact PI
CRLF2 signaling in B-cell acute lymphoblastic leukemia$334,423
R01 · FY2011 · CA · contact PI
CRLF2 signaling in B-cell acute lymphoblastic leukemia$354,445
R01 · FY2010 · CA · contact PI